Significance of monitoring imatinib plasma concentration in second-line treatment decisions for c-kit 11 gene-mutated gastrointestinal stromal tumors

Figure 1 Flowchart of patient selection. A total of 998 patients diagnosed with gastrointestinal stromal tumors (GISTs) were extracted from our database; 75 patients ultimately met the eligibility criteria for the final analysis. Based on their drug plasma concentrations, these patients were categorized into two groups: Low plasma (LP) concentration group (< 1100 ng/mL) and high plasma (HP) concentration group (≥ 1100 ng/mL). IM: Imatinib; TKI: Tyrosine kinase inhibitor.